Related Experiment Video
Updated: Feb 22, 2026
Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
Published on: July 28, 2023
Double strain probiotic effect on Helicobacter pylori infection treatment: A double-blinded randomized controlled
Mehdi Haghdoost1, Sepehr Taghizadeh1, Majid Montazer2
1Department of Infectious Diseases, Tabriz University of Medical Sciences, Tabriz, Iran.
Background:
A decreased rate of successful helicobacter pylori (H.pylori) infection treatment has revealed serious demand for more effective regimens to eradicate infection. Therefore, probiotics have recently been considered to increase the rate of antibiotic regimens efficacy in H. pylori infections. In current randomized controlled trial, we evaluated the effect of double strain probiotic combination with standard triple therapy (STT), in the eradication rate of H. pylori infection.
Methods:
In current randomized placebo-control study, all patients (176 subjects) underwent the STT for 10 days. However, the study group received triple therapy for the eradication of H. pylori with supplement of Lactobacillus probiotic for 4 weeks and placebo was administered to control group, as well. Adverse effects of the antibiotic regimen were recorded for all patients. Six weeks after the cessation of probiotic intake, all patients underwent H. Pylori with fecal antigen of test, followed by a recurrence evaluation six months later.
Results:
There was no significant difference in demographic data and presenting symptoms between the study groups. The eradication rate of H. pylori infection was significantly higher in probiotic group (78.4%), compared to that of placebo group (64.8%) (P=0.033). In addition, adverse events were significantly less prevalent in patients that received probiotic (P=0.047). Nonetheless, there was no significant difference in terms of infection recurrence during a 6-month follow-up (P=0.07).
Conclusion:
Double strain probiotic in combination with STT increased the eradication rate of H. pylori infection, while the adverse events due to antibiotic therapy decreased.
Insights
Adding probiotics to standard triple therapy significantly boosted Helicobacter pylori eradication rates and reduced adverse effects. This combination offers a more effective treatment for H. pylori infections.
Area of Science:
- Gastroenterology
- Microbiology
- Pharmacology
Background:
- Decreasing efficacy of standard treatments for Helicobacter pylori (H. pylori) necessitates novel therapeutic strategies.
- Probiotics are being investigated as adjuncts to antibiotic regimens to improve H. pylori eradication rates.
- This study assesses a double-strain probiotic combined with standard triple therapy (STT).
Purpose of the Study:
- To evaluate the efficacy of a double-strain probiotic in enhancing the H. pylori eradication rate when used with STT.
- To assess the impact of probiotic supplementation on the incidence of adverse events associated with H. pylori antibiotic therapy.
- To determine if probiotic use affects H. pylori infection recurrence over a six-month follow-up period.
Main Methods:
- A randomized, placebo-controlled trial involving 176 subjects undergoing a 10-day course of STT.
- The intervention group received a Lactobacillus probiotic supplement for 4 weeks alongside STT; the control group received a placebo.
- H. pylori eradication was confirmed via fecal antigen testing 6 weeks post-treatment, with recurrence monitored for 6 months.
Main Results:
- The H. pylori eradication rate was significantly higher in the probiotic group (78.4%) compared to the placebo group (64.8%) (P=0.033).
- Patients receiving probiotics experienced significantly fewer adverse events (P=0.047).
- No significant difference in infection recurrence was observed between groups over the 6-month follow-up (P=0.07).
Conclusions:
- Combination therapy with a double-strain probiotic and STT enhances H. pylori eradication.
- Probiotic supplementation can mitigate adverse effects commonly associated with H. pylori antibiotic treatments.
- The addition of probiotics to STT does not significantly alter H. pylori recurrence rates within a six-month timeframe.
More Related Videos
03:47Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
05:23Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.